From IIT Bombay to continuous manufacturing platforms—how one leader’s 18-year journey across Amgen, Regeneron, and Indian biotech is redefining what’s possible in biologics development
Most biotechnology leaders pick a lane: deep technical expertise or broad operational leadership, Big Pharma scale or biotech agility, innovator molecules or biosimilars execution. Dr. Abhishek Mathur has systematically refused to choose, building instead a career that bridges chemical engineering and biological sciences, spans continents and company scales, and integrates CMC technical depth with strategic business thinking and operational excellence.
With a BTech in Chemical Engineering from IIT Bombay and PhD in Biological Sciences from Northwestern University, Dr. Mathur’s disciplinary foundation already signalled unconventional thinking. His 18-year career trajectory—spanning Amgen’s innovator biologics and biosimilars functions, Regeneron’s rapid commercialisation engine, Catalent’s CDMO operations, global R&D partnership leadership, and now executive roles building India’s biologics capabilities at Biolexis and Enzene Biosciences—demonstrates rare versatility executing across dramatically different operating contexts.
As SVP and Head of R&D at Enzene Biosciences, Dr. Mathur advanced proprietary continuous manufacturing platforms whilst leading novel therapeutics discovery. Previously as CSO at Biolexis (a Strides company), he built biologics portfolios targeting regulated US and EU markets, navigating the transition from Big Pharma infrastructure to India’s more resource-conscious biotech ecosystem. His Amgen tenure included foundational years establishing biological characterisation functions, followed by directing global R&D operations managing external partnerships across Europe, China, and India—experience culminating in relocating to India to deepen collaboration with key partners.
His MBA from Duke’s Fuqua School of Business complements technical credentials, enabling fluency in business strategy, financial evaluation, and partnership structuring that pure scientists often lack. This combination—deep CMC expertise, operational leadership across multiple contexts, strategic business thinking, and cross-cultural partnership experience—positions Dr. Mathur uniquely to assess where India’s biologics sector stands and what capabilities must be built to compete globally in novel biological entities rather than remaining primarily biosimilars-focused.
What emerges from conversation with Dr. Mathur is perspective grounded in practical execution rather than theoretical speculation. He’s navigated FDA and EMA regulatory submissions, managed analytical operations under tight financial constraints, built cross-functional teams spanning continents, and made the difficult transition from well-resourced Big Pharma environments to capital-constrained Indian biotechs where every decision directly impacts program viability. This breadth informs views on critical capability gaps, emerging technology convergences, and what criteria separate commercially viable biologic assets from promising science unlikely to reach patients.
Ahead of his keynote at the Bioxyra Summit, we explored the pivotal experiences shaping his perspective, the technical and strategic lessons informing his leadership approach, and his candid assessment of what Indian biologics companies must prioritise to evolve beyond biosimilars into genuine innovation competitors.
Foundations: From Engineering Principles to Biological Complexity
The disciplinary bridge from chemical engineering to biological sciences often proves difficult to cross successfully. The quantitative, deterministic thinking characterising engineering conflicts with biology’s inherent variability and complexity. Dr. Mathur’s successful navigation of this transition reveals how fundamental principles transfer across domains when approached with appropriate mindset.
Your journey began with BTech in Chemical Engineering from IIT Bombay, followed by PhD in Biological Sciences at Northwestern University. That’s an interesting disciplinary bridge. What pivotal research experience during your doctoral work sparked your passion for biologics CMC development, and how have those chemical engineering principles proven foundational when tackling biological molecules’ complexities?
“Honestly, the bridge made more sense in hindsight than it did when I first crossed it. I went into graduate school driven more by what I wanted to work on—solving hard biological problems like cancer—than by a clear picture of how I would get there. During my senior year at IIT Bombay, I took my first deep dive into molecular and cellular biology through coursework and a biotechnology thesis. I was struck by how logical biological systems are once you understand the rules. That realisation made the leap from traditional Chemical Engineering into Biological Sciences feel less like a jump and more like an expansion of the same problem-solving mindset.
The pivotal moment during my PhD at Northwestern came when I joined a biomedical engineering lab developing a highly miniaturised, ultra-high-throughput screening platform capable of running over a million diagnostic tests rapidly. We were combining biochemistry, advanced imaging, and early machine learning approaches, all under strict constraints of sensitivity, speed, and reproducibility. My role leaned heavily on experimental design, quantitative imaging, and statistics. That experience fundamentally shaped how I think about biological systems—not as mysterious black boxes, but as measurable, optimisable systems governed by variability, signal-to-noise, and design trade-offs. That quantitative lens is what later opened the door for me to join Amgen in a potency assay group, even though I didn’t come in with deep hands-on cell biology experience.
From there, my passion naturally evolved toward biologics CMC. Chemical engineering principles turned out to be incredibly transferable. Process development for biologics is, at its core, a complex design problem: defining critical quality attributes, understanding how process parameters drive molecular structure and function, managing variability, and building robust control strategies. Concepts like mass balance, kinetics, transport phenomena, and statistical design of experiments became tools for understanding cell culture behaviour, purification performance, and product stability. Just as importantly, engineering trained me to keep the ‘whole process’ in view—upstream, downstream, analytics, and ultimately the patient—rather than getting locked into a single technique. That systems-level thinking has been foundational in navigating the complexity of biological molecules and in contributing meaningfully to product development and commercialisation.
One belief that’s consistently guided me is that biotechnology is incredibly broad—and even more so today with technology woven into it. Staying open to learning from unexpected places really matters, because the human brain is remarkably good at connecting dots that don’t seem related at first. That’s often where the most innovative solutions come from.”
The description of biological systems as “measurable, optimisable systems governed by variability, signal-to-noise, and design trade-offs” captures engineering mindset’s value when applied to biology. Where purely biological training might accept inherent variability as unavoidable, engineering thinking asks how variability can be measured, controlled, and minimised through systematic process design. This quantitative approach proves essential for biologics manufacturing, where consistency and reproducibility determine whether products meet regulatory standards and achieve commercial viability.
The emphasis on “whole process” thinking addresses common failure mode where specialists optimise individual unit operations without considering system-level implications. Upstream improvements increasing cell culture productivity prove counterproductive if downstream purification becomes saturated; analytical methods providing exquisite sensitivity waste resources if variability stems from upstream inconsistency. Systems perspective ensures optimisation efforts target true constraints rather than local bottlenecks whose improvement merely shifts problems elsewhere.
Starting at Amgen as Scientist and Senior Scientist from 2006 to 2014, you built and led the Biological Characterisation function, managing bioassays for both innovator biologics and biosimilars. What were the most valuable technical lessons you learned during those formative years that continue to guide your approach to product lifecycle management today?
“By the time I finished my PhD, I had developed a structured way of tackling complex scientific problems—which, in many ways, is one of the most valuable skills doctoral training gives you. I’ve always felt fortunate that Amgen became my first real ‘school’ of professional learning. Surrounded by top scientists focused on doing top science, those years taught me how to think about biologics as integrated systems rather than isolated experiments. Biological molecules are inherently complex and variable, so understanding them requires a combination of strong experimental design, statistical thinking, and a clear link between molecular attributes and biological function. I learned to be very deliberate about how we generate and interpret data, always asking whether results are truly telling us something about the molecule or just reflecting noise in the system.
Another key lesson was the importance of connecting science with the broader development pathway. As I grew into leadership roles, I saw how early scientific decisions influence manufacturing, regulatory strategy, and ultimately long-term product performance. That built my habit of stepping back to see the full picture—how development, analytical understanding, process knowledge, and clinical goals all need to align.
Equally important was a parallel lesson about purpose and responsibility. One of Amgen’s core values is to ‘Do the right thing,’ rooted in integrity, ethics, and a deep commitment to patients. It’s a phrase you hear often, but its true meaning only becomes clear in certain defining moments. In my first month or so at the company, a cancer survivor visited and spoke to employees about how a therapy—’Epogen’ from Amgen—had transformed her life and enabled her to get back on her feet. The kind of gleam and thankfulness she expressed toward Amgen and the scientists who had spent years bringing the therapy to patients was incredibly moving and deeply striking, especially for those of us who were just beginning our journeys at the company. In that moment, the meaning of doing things the right way became very real. It underscored the privilege and the responsibility of working on therapies that can profoundly affect patients and their families. That experience has remained a lasting source of motivation, particularly on the tougher days.
As I progressed in my career and began leading teams and larger functions, I carried that perspective forward. It’s important to help every member in the organisation understand the purpose behind their work, that what we do today could directly affect someone’s life tomorrow. That mindset reinforces the need to stay grounded in sound science, uphold the highest quality standards, and address any issues with transparency and urgency. Ultimately, everything we do—whether in the lab or in manufacturing—is aimed at ensuring that the medicine reaching patients is safe, effective, and of the highest possible quality.
Those formative lessons—woven with scientific discipline, systems thinking, and an unwavering focus on patients—continue to guide how I approach product development and its lifecycle management today.”
The distinction between signal and noise—”whether results are truly telling us something about the molecule or just reflecting noise in the system”—proves crucial in biologics development where inherent biological variability can obscure genuine molecular differences. Rigorous experimental design, appropriate statistical analysis, and healthy scepticism about preliminary results prevent chasing artifacts whilst ensuring real differences receive appropriate attention.
The patient encounter represents more than motivational anecdote—it embodies why rigorous science, quality systems, and regulatory compliance matter beyond abstract principles. The cancer survivor’s transformation through Epogen wasn’t inevitable; it required scientists making correct technical decisions years earlier, manufacturing teams maintaining consistent quality, regulatory professionals navigating approval pathways, and commercial teams ensuring access. Every function’s contribution ultimately served the patient whose life changed profoundly.
Navigating Complexity: From Innovator Speed to CDMO Efficiency
Dr. Mathur’s career progression exposed him to dramatically different operating contexts—each with distinct challenges, constraints, and success metrics. This breadth informs nuanced understanding of how context shapes what’s possible and what strategies prove effective.
At Regeneron (2014-2017) as Associate Director, you supported commercialisation of five drugs whilst transitioning eight pipeline programmes from R&D to late phase. How did you balance intense regulatory timelines of BLA submissions with maintaining scientific innovation under analytical pressures of quality control environments?
“At Regeneron, I joined at a time when the company was rapidly evolving—energised by the success of Eylea® and powered by a highly productive discovery engine. What stood out immediately was the strong cultural foundation around quality systems. That emphasis on quality wasn’t seen as a bottleneck; it was viewed as the enabler that ensured only the most robust molecules advanced. In a fast-growing organisation with multiple programmes moving quickly, that mindset was essential.
Balancing aggressive BLA timelines with scientific rigour required intention in every step. From day one, we embedded Quality by Design into our development and analytical strategies—not just as a framework, but as a mindset, making every decision accountable to quality. By emphasising structured experimental design, risk assessment, and early understanding of method performance, we built approaches that were both fit-for-purpose and resilient through late-phase and commercial stages.
We also leaned heavily into efficiency through smart use of automation and streamlined workflows. That combination of strong scientific design and operational efficiency significantly shortened development cycles whilst improving robustness. Over time, method development timelines were reduced by roughly half, and failure rates dropped substantially. That reliability translated directly into smoother regulatory submissions, with fewer major surprises or difficult questions during review.
Equally important was investing in the team’s scientific understanding. I spent a lot of time ensuring that our bench-level scientists understood the strategic and scientific rationale behind our approaches—not just what we were doing, but why. When teams internalise that mindset, innovation doesn’t disappear in a quality-focused environment; it becomes more targeted and impactful. People start designing better experiments, anticipating risks earlier, and proposing smarter solutions that still meet regulatory expectations.
In hindsight, it was a period where the team rallied around a shared goal: building a world-class function within a world-class organisation. Once we were aligned on that purpose, the ‘how’—balancing speed, compliance, and scientific innovation—became much more achievable.”
The framing of quality as “enabler that ensured only the most robust molecules advanced” rather than bottleneck reveals sophisticated understanding. Weak quality systems allow flawed molecules to advance, wasting resources on programmes ultimately doomed by fundamental deficiencies only apparent later. Rigorous quality systems functioning as filters prevent this waste, concentrating resources on candidates with genuine commercial potential.
The achievement—method development timelines halved, failure rates dropped substantially—demonstrates that quality and speed aren’t necessarily opposing forces. Well-designed processes incorporating Quality by Design principles from inception often prove faster than reactive approaches where quality problems discovered late require expensive remediation. The reliability translating into “smoother regulatory submissions” validates this approach: time invested upfront in robust method development pays dividends through reduced regulatory friction.
Your Director role at Catalent Pharma Solutions (2017-2018) focused on biologics analytical operations across both GxP and non-GxP programmes. What operational excellence frameworks did you implement to achieve corporate financial objectives whilst championing continuous improvement?
“At Catalent, the operating environment was very different from a traditional biopharma company. As a CDMO, each site had to be financially self-sustaining, often working with tight margins and fluctuating demand. Leading biologics analytical operations across both GxP and non-GxP programmes gave me a front-row view of how critical operational discipline is to both financial performance and client trust.
One of the biggest opportunities I identified was the disconnect between business development commitments and the actual technical capacity to deliver. Projects were being accepted with ambitious timelines, but without a structured assessment of lab bandwidth, infrastructure readiness, or scientific resource availability. That led to schedule pressure, reactive firefighting, and inefficiencies that affected both team morale and financial outcomes.
To address this, I implemented a formal project and resource planning framework within the analytical organisation. We developed rolling three-month capacity views that mapped active and anticipated projects against available instruments, lab space, and staff. This created transparency around what we could realistically deliver and when. I also established a regular cross-functional forum between business development and technical teams so that potential opportunities could be reviewed early for feasibility, timelines, and resource impact before commitments were finalised.
Another important element was strengthening forecasting and accountability with clients. We worked with both existing and new partners to provide rolling forecasts of expected work, which allowed us to plan proactively. At the same time, we clarified mutual responsibilities around timelines—we remained flexible and solutions-oriented, but changes in scope or delays in sample delivery were clearly reflected in project schedules. This helped drive more disciplined planning on both sides.
These frameworks improved predictability and execution. On-time delivery increased, last-minute escalations decreased, and overtime was significantly reduced. From a financial standpoint, better capacity planning and fewer disruptions improved operational efficiency towards supporting site revenue goals. Just as importantly, our credibility with clients strengthened because we were making realistic commitments and consistently meeting them.
A key lesson from that experience is that operational excellence in a CDMO environment depends on building robust systems rather than relying on individual heroics or firefighting ability. Sustainable performance comes from clear processes that align sales, science, and operations. I have to credit my leadership team and the broader analytical organisation therein, who were instrumental in adopting these tools and driving continuous improvement on the ground.”
The diagnosis—”disconnect between business development commitments and the actual technical capacity to deliver”—identifies common failure mode in service organisations where commercial pressures drive unrealistic commitments. Sales teams incentivised on deals closed rather than projects successfully delivered naturally push optimistic timelines; technical teams absorb resulting pressure through heroic efforts that prove unsustainable.
The three-month rolling capacity planning addresses this systemically by creating transparency forcing honest conversations about feasibility before commitments finalize. When everyone sees current capacity utilisation and upcoming demands, unrealistic commitments become immediately visible rather than hidden until execution failures emerge. The cross-functional forum institutionalises this transparency, ensuring commercial and technical perspectives inform decisions jointly.
As Director of Global R&D Operations (Biologics) at Amgen (2018-2022), you led externalisation strategies and operationalised novel technology integrations. What were key cultural differences you observed between Amgen’s internal R&D model and managing strategic global partnerships, and how have these experiences shaped your leadership philosophy?
“Moving back to Amgen felt like coming back home. In this role, one of my primary focus areas was establishing a strong operational continuum between Amgen R&D organisation and our global external partners. Having seen both innovator and CDMO models, I understood how easily misalignment can occur between a sponsor’s expectations and a partner’s execution reality. I worked to ensure that external teams were not just delivering tasks, but clearly understood how their work fit into Amgen’s broader discovery and development ecosystem—including data standards, decision gates, timelines, and new technology integration. That end-to-end alignment improved predictability, reduced rework, and allowed externally generated data and capabilities to plug more seamlessly into internal programmes.
Alongside the operational alignment, the cultural dimension became an equally important and deeply enriching aspect of the role. Collaborating with partners across Europe, China, and India highlighted how communication styles, approaches to hierarchy, and ways of expressing risk or disagreement vary significantly. These differences weren’t barriers, but they did require greater awareness and adaptability in leadership. A principle that resonated strongly with me—and that I often kept in mind—comes from Erin Meyer (Professor at INSEAD, and author of ‘The Culture Map’), who puts it so aptly, ‘When interacting with someone from another culture, try to watch more, listen more, and speak less.’ Practising that mindset helped me better interpret nuance, read between the lines when needed, and create space for more open dialogue.
A particularly meaningful part of this journey was the opportunity to relocate to India and work closely with one of our key collaborators there. Being on the ground allowed me to build deeper relationships and gain a much more nuanced understanding of local working styles, motivations, and strengths. At the same time, I could help bridge expectations by clarifying how Amgen approaches communication, accountability, and execution. It became a two-way learning process—for me, for my colleagues at Amgen, and for our partners.
My experience in this role was incredibly rewarding and shaped my leadership philosophy in a lasting way. I came to believe strongly in being clear about standards and outcomes, whilst remaining flexible and culturally aware in how we achieve them. Effective global leadership, in my view, is built on trust, empathy, and shared purpose—when those elements are in place, both innovation and execution become much stronger.”
The emphasis on ensuring external partners “clearly understood how their work fit into Amgen’s broader… ecosystem” addresses common partnership failure mode where external teams execute specified tasks competently but without understanding strategic context. This creates brittleness: when unexpected results emerge or circumstances change, external teams lacking broader context cannot adapt appropriately without extensive back-and-forth communication. Investing upfront in shared understanding enables autonomous decision-making aligned with sponsor’s ultimate objectives.
The relocation to India represents commitment to partnership that superficial engagement cannot replicate. Video calls and periodic visits provide limited understanding of local context, working styles, and unspoken dynamics shaping how work actually gets done. Physical presence enables relationship-building, cultural learning, and trust development that remote engagement struggles achieving. The characterisation as “two-way learning process” acknowledges that partnership value flows bidirectionally when approached with genuine openness rather than hierarchical sponsor-vendor dynamics.
India’s Biologics Evolution: From Biosimilars Capability to Innovation Ambition
Dr. Mathur’s return to India—first at Biolexis, then Enzene—positioned him uniquely to assess India’s biologics sector from dual perspectives: someone who understands global innovation leaders’ capabilities and expectations, whilst also experiencing Indian biotechs’ resource constraints and strategic challenges firsthand.
Joining Biolexis Pvt Ltd (a Strides company) as Chief Scientific Officer (2022-2023), you built a biologics portfolio for regulated US and EU markets whilst handling CMC, clinical, and regulatory strategy. How did you navigate the transition from US Big Pharma infrastructure back to India’s more agile biotech ecosystem, particularly around cell line onboarding and co-development partnerships?
“Joining Biolexis as CSO was both a professional homecoming to India and a strategic shift from the scale of U.S. big pharma to a far more agile, resource-conscious biotech environment. India’s biologics sector was at an inflection point—strong scientific talent, a maturing regulatory framework, and a strong focus on delivering high-quality, affordable biologics for regulated markets like the US and EU.
The most significant shift for me was embracing an approach that prioritised efficiency whilst never compromising on quality—a philosophy I carried forward into my subsequent roles, maintaining continuity in how development programmes were structured and delivered.
In large pharma, scale can sometimes absorb inefficiencies; in an emerging biotech, every decision—from cell line strategy to clinical planning—directly affects programme viability. That drove a strong emphasis on risk-based, science-led development: understanding product and process risks early, designing experiments thoughtfully, and using data to guide decisions rather than relying on iterative trial and error.
Cell line onboarding was a good example of this shift. We treated it as a strategic decision tied to long-term manufacturability, regulatory expectations, and cost of goods. Rapid but thorough technical and IP landscaping, platform compatibility assessments, and careful partner selection ensured that speed did not come at the expense of commercial robustness.
Co-development partnerships were equally important. In a lean ecosystem, external collaborators function as an extension of your organisation. We focused on transparent, science-driven relationships with early alignment on timelines, data standards, and regulatory strategy. Proactive engagement with regulatory agencies helped us design efficient development pathways, including scientifically justified opportunities for clinical waivers.
Operationally, we aimed to be ‘smart by design’—leveraging platform technologies, available automation, and digital tools whilst keeping teams tightly aligned on programme priorities. The goal was to compress timelines and manage costs without diluting product quality, which is essential when affordability is part of the mission.
Overall, this phase of my career reinforced that innovation is as much about how we work as it is about the science itself. Leading in India’s agile biotech ecosystem strengthened my ability to make high-impact decisions with limited resources, build strong partnerships, and consistently deliver globally acceptable quality in a cost-conscious framework.”
The observation that “every decision… directly affects programme viability” captures resource-constrained environments’ unforgiving nature. Big Pharma can absorb suboptimal decisions through redundant resources, backup plans, and financial buffers; biotechs cannot. This demands different decision-making discipline where thorough upfront analysis prevents expensive mistakes that bigger organisations might survive but startups cannot.
The cell line example illustrates this principle practically. Large organisations might evaluate multiple cell lines in parallel, allowing experimental data to guide final selection; resource-constrained biotechs must narrow options through rigorous technical and IP analysis before expensive experimental work begins. This “smart by design” approach requires more sophisticated upfront thinking but enables comparable outcomes with dramatically reduced resource consumption.
You previously served as SVP and Head of R&D at Enzene Biosciences (2023–2025), where you advanced its proprietary continuous manufacturing platform alongside novel therapeutics discovery. Could you share the key technical innovations behind continuous manufacturing for biologics and how Enzene’s approach differed from traditional batch-based processes?
“The vision behind Enzene’s proprietary continuous platform was to rethink biologics manufacturing from the ground up. Traditional antibody production relies on discrete, large-scale batch steps with significant hold times, scale-up complexity, and high infrastructure costs. Its platform was designed as an end-to-end connected continuous platform, where upstream and downstream operations are integrated into a steady, controlled flow rather than isolated unit operations.
A central technical innovation in continuous biologics production is the coupling of perfusion-based cell culture with continuous downstream purification. Instead of intermittent fed-batch runs, cells are maintained in a highly productive state over extended durations, with product harvested and purified in a linked, ongoing stream. Achieving this requires advanced control strategies, real-time monitoring, and stable operating conditions to ensure consistent product quality over long campaigns. The payoff is a smaller manufacturing footprint, higher volumetric productivity, and more efficient use of materials and equipment.
Another important aspect is modularity and platform thinking. Continuous systems are often designed around adaptable platform parameters rather than molecule-specific, one-off processes. This enables faster tech transfer, more predictable performance, and easier integration of automation and digital tools. The result is tighter process control and richer datasets that strengthen both consistency and regulatory confidence.
Compared with traditional batch manufacturing, the benefits extend beyond technical performance. Continuous manufacturing changes the economics and risk profile of production: scaling is achieved by running longer, not by building larger facilities. This reduces capital investment, shortens timelines, and has the potential to significantly lower cost of goods.
What makes this especially impactful is the broader implication for access. Continuous and other disruptive manufacturing technologies can help democratise biologics production, making high-quality therapies more affordable worldwide. For the industry, investing in such forward-looking manufacturing models is not only a strategic advantage but also a meaningful step toward expanding patient access on a global scale.”
The economic transformation—”scaling is achieved by running longer, not by building larger facilities”—represents fundamental shift in biologics manufacturing paradigm. Traditional batch manufacturing scales through increasingly large bioreactors requiring proportionally larger facilities, utilities, and capital investment. Continuous manufacturing scales through time rather than size, dramatically reducing infrastructure requirements whilst maintaining or improving output.
The emphasis on “democratise biologics production, making high-quality therapies more affordable worldwide” connects technical innovation to access imperatives. Novel biologics’ transformative therapeutic potential remains largely theoretical for billions lacking access due to prohibitive costs. Manufacturing innovations substantially reducing production costs whilst maintaining quality could transform biologics from luxury goods accessible only in wealthy markets into globally available therapeutics.
Your career uniquely spans deep technical CMC expertise, operational leadership, and strategic business development (MBA from Duke, 2015-2016). When evaluating early-phase biologic assets for in-licensing or partnership opportunities, what are your top three criteria that separate potential commercial successes from likely pipeline failures?
“That’s a great question, because in early-phase biologics, the science is only half the story. Having worked across CMC, operations, and business strategy, I’ve learned that the assets most likely to become commercial successes tend to align on three dimensions simultaneously:
- a) Developability needs to be built in, not bolted on later: The first filter is molecule quality from a CMC and manufacturability standpoint. Many biologics look promising biologically but are fundamentally flawed as products.
I look for:
- Favourable biophysical properties (stability, aggregation profile, solubility)
- Reasonable expression yields and scalability potential
- A molecule that is amenable to platform processes, not one requiring heroic, bespoke solutions
If a candidate already shows red flags in formulation, stability, or manufacturability at the early stage, the downstream cost, delay, and risk often outweigh the biological promise. Commercial success usually correlates with druggability and developability being considered early, not rescued later.
- b) Clear and differentiated clinical value: Second is unambiguous differentiation in the clinic, not just ‘another molecule in the class.’
I ask:
- Does this asset solve a real limitation of existing therapies? (efficacy, safety, dosing, resistance, patient segment)
- Is there a biomarker or patient stratification strategy that increases probability of success?
- Is the mechanism supported by strong human biology, not just preclinical promise?
Programmes have a greater tendency to fail commercially when they enter crowded landscape and offer only marginal benefits. The commercial success is typically an outcome of a clear narrative around why the product matters clinically, which also drives regulatory, payer, and physician adoption.
- c) A credible path to efficient development and market access: Finally, I assess whether there is a realistic operational and commercial pathway, not just a scientific hypothesis.
This includes:
- A development plan that matches the biology (right indications, smart trial design, feasible endpoints)
- Regulatory clarity: Is there precedent or a viable pathway?
- A market where the product profile supports reimbursement and adoption, not just approval
A technically sound molecule in an impractical indication or an unworkable trial design is just as risky as a weak molecule. Commercially successful biologics usually are driven by a concoction of strong science, executable development, and a market that can absorb the innovation.”
The emphasis on developability “built in, not bolted on later” reflects hard-won understanding that manufacturability problems discovered late often prove insurmountable regardless of biological promise. Molecules requiring “heroic, bespoke solutions” for manufacturing may work at research scale but fail catastrophically during commercial scale-up when consistency, reliability, and economics become paramount.
The clinical differentiation criterion—”solve a real limitation of existing therapies”—addresses the “me-too” molecule trap where programmes pursue crowded indications offering marginal improvements. Even technically successful development culminating in regulatory approval generates limited commercial value when physicians see insufficient reason switching from established therapies. Clear differentiation narrative drives not just regulatory approval but actual adoption determining commercial success.
India is emerging as a biologics powerhouse, and you’ve witnessed this evolution from both US and Indian perspectives. What are the three most critical capability gaps Indian biotech companies must close to compete with global leaders in novel biological entities, rather than remaining primarily a biosimilars hub?
“Another great question, and a very timely one. India has been maturing well in process development, cost-efficient manufacturing, and biosimilars execution, and facing an enormous opportunity with evolving and arguably easing regulatory burden. But competing in novel biologics requires a different muscle set. From my experience working across both US and Indian ecosystems, three capability gaps stand out.
- a) Translational Science and Early Clinical Strategy: India has strong discovery biology and excellent technical talent, but what’s often missing is tight integration between discovery, translational science, and clinical strategy.
Global innovators deeply invest their efforts and time excelling at:
- Selecting the right indication and patient segment early
- Building biomarker and translational plans alongside the molecule
- Designing early trials to answer go/no-go questions quickly, not just show safety
Many programmes in India still advance based on promising preclinical data without a deeply thought-out translational roadmap. To compete globally, companies must invest more in human biology, biomarker strategy, and early clinical decision science, not just molecule generation.
- b) Product-Focused CMC and Developability Mindset: India is outstanding at manufacturing execution—but novel biologics demand a product mindset, not just a process mindset.
Leading innovators build developability into the molecule from day one, asking:
- Is this molecule stable, manufacturable, and scalable?
- Can it fit within platform processes and realistic COGS?
- Will formulation, delivery, or stability limit global use?
In biosimilars, the target is defined. In novel biologics, you define the target product profile yourself, and poor early CMC choices can quietly derail otherwise strong assets. India needs deeper integration of CMC thinking at the discovery stage, not after candidate selection.
- c) Risk Appetite, Portfolio Thinking, and Capital Efficiency: Innovator biologics is fundamentally a portfolio and probability business. Not all programmes will succeed, and global leaders are deliberately structured to manage that risk.
From this standpoint, the critical gaps are:
- Institutional comfort with terminating programmes early based on data
- Building diversified pipelines rather than overcommitting capital to a single asset—an ongoing challenge under funding constraints, where sustainable capital sources and targeted participation from government and private investors can be highly impactful
- Aligning capital allocation strategies with the long timelines and inherent uncertainty of innovative R&D
Whilst the biosimilar model rewards execution, efficiency and predictability, innovative biologics require disciplined risk-taking, staged investment, and rigorous decision-making. Global leaders succeed by managing R&D as a portfolio of options, not a single concentrated bet. That said, as the Indian biologics diaspora evolves, portfolio-oriented initiatives are gaining traction and momentum is clearly building. Government initiatives (BioE3, Biopharma Shakti initiative) should bring direct focus on novel biologics with dedicated channels. This focus should further reinforce positive sentiment and encourage both established organisations and emerging companies to accelerate investment in their innovative biologics engines.”
The translational science gap—programmes advancing “based on promising preclinical data without a deeply thought-out translational roadmap”—identifies common failure mode. Animal models often prove poor predictors of human outcomes; molecules showing dramatic preclinical efficacy frequently disappoint in clinical trials. Robust translational strategies incorporating human biology, biomarker development, and patient stratification substantially improve probability that preclinical promise translates into clinical benefit.
The product versus process mindset distinction proves particularly insightful. Biosimilars manufacturing optimises known target products; excellence requires process execution. Novel biologics demand defining target product profiles themselves—requiring integration of CMC thinking from discovery onset rather than treating manufacturability as downstream problem addressed after candidate selection. This fundamental mindset shift challenges organisations whose success derived from execution excellence rather than upfront strategic thinking.
Looking ahead 5 to 10 years, what emerging convergences—whether AI and machine learning for biopharma, multi-specific antibodies, continuous manufacturing at scale, or others—do you believe will fundamentally redefine biologics development? How are upcoming companies positioning themselves at these technological frontiers?
“As we talk today, biologics development is already being reshaped not by isolated breakthroughs, but by the convergence of biology, data, and advanced manufacturing. In coming decade, AI and machine learning will increasingly guide decisions from target selection to clinical strategy, enabling faster learning and more disciplined risk-taking. At the same time, engineered and multi-specific biologics will move from experimental formats to precision tools for addressing complex disease biology. Continuous and digitally enabled manufacturing will emerge as a strategic advantage, improving speed, scalability, and reliability.
More tangible outcomes and success stories in next few years, are only going to reinforce the new paradigm, in which the seamless integration of science and technology is not just expected, but foundational to every innovation.
The most successful companies globally, both established and emerging, are already positioning themselves by building integrated platforms rather than linear pipelines, investing early in enabling technologies, and developing talent that operates at the intersection of science, engineering, and data. Ultimately, the future of biologics will belong to organisations that combine technological ambition with patient focus, people-centric leadership, and portfolio discipline.”
The framing—”convergence of biology, data, and advanced manufacturing” rather than isolated breakthroughs—captures how innovation increasingly occurs at disciplinary intersections. AI alone cannot design better biologics without understanding biological constraints; continuous manufacturing requires integration with robust analytical methods and process control; multi-specific antibodies demand both discovery innovation and manufacturing capability. Success requires orchestrating multiple capabilities simultaneously rather than excelling in single dimension.
The emphasis on “integrated platforms rather than linear pipelines” distinguishes sustainable innovation models from one-off successes. Linear pipelines produce individual products; platforms enable systematic candidate generation, development, and manufacturing across multiple programmes. Platform investments prove more capital-intensive initially but generate compounding returns as successive programmes leverage established infrastructure and capabilities.
Looking Forward: The Bioxyra Summit and Collective Progress
As our conversation concludes, Dr. Mathur reflects on the role gatherings like Bioxyra Summit play in advancing India’s biologics sector beyond individual company achievements toward ecosystem-level transformation.
“The biologics sector’s evolution requires more than isolated company successes—it demands collective capability-building, knowledge-sharing, and coordinated action addressing systemic challenges no single organisation can solve independently,” Dr. Mathur observes.For Dr. Mathur, the summit’s value extends beyond formal presentations into substantive conversations about shared challenges. “When someone from continuous manufacturing discusses operational challenges, someone from regulatory affairs might recognise parallel issues they’ve solved in different context.
The broader vision involves India’s biologics sector evolving from capability importer to capability exporter—not merely executing processes developed elsewhere but pioneering approaches that global industry adopts.
Dr. Mathur’s participation at the Bioxyra Summit brings perspective spanning academic research, Big Pharma operations, CDMO efficiency, global partnerships, and Indian biotech leadership. The Bioxyra Summit, by bringing together leaders who’ve navigated similar journeys alongside those charting new paths, accelerates the collective learning and collaborative problem-solving essential for India’s biologics sector to fulfill its potential as global innovation leader, not merely capable manufacturer.
Dr. Abhishek Mathur will be a featured speaker at the Bioxyra Summit, where he will share insights from his 18-year journey across biologics CMC development, operational leadership, global partnerships, and building India’s innovation capabilities. His perspectives on capability gaps, evaluation criteria for biologic assets, and emerging technology convergences will inform attendees navigating India’s biologics sector evolution from biosimilars strength toward novel biologics innovation.